Noninvasive Prenatal Test (NIPT)
Novelvi® can be performed as soon as 10 weeks into pregnancy to evaluate the health of the developing fetus. The test screens for chromosomal abnormalities (aneuploidy) which can be associated with severe syndromes. Our Novelvi® panels use the latest sequencing technology to deliver extremely accurate results. Learn more about our two panels below.
Screens for the 3 most common aneuploidies:
Screens all 24 chromosomes for aneuploidy plus clinically relevant microdeletions. These include:
Progenesis is a San Diego based company that develops and offers genetic testing services for patients throughout their family planning journey. Progenesis was the first company in the U.S. to offer Next Generation Sequencing (NGS) for preimplantation genetic testing. Through optimization of the NGS platform, Progenesis confidently maintains the most accurate testing in the IVF field with the lowest rate of mosaicism.